FindTrial
Sign In

A prospective study on the use of machine learning technology to assist in the precise use of meropenem PK-PD in critically ill patients with severe infections in the real world

A prospective study on the use of machine learning technology to assist in the precise use of meropenem PK-PD in critically ill patients with severe infections in the real world

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500096891
Enrollment
Unknown
Registered
2025-02-08
Start date
2024-04-17
Completion date
Unknown
Last updated
2025-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bacterial infection

Interventions

Case series:No intervention

Sponsors

Fuwai Yunnan Cardiovascular Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 85 Years

Inclusion criteria

Inclusion criteria: 1. Patients with critical illness, such as hemodynamic instability, organ failure, and requiring mechanical ventilation; 2.Patients with pulmonary infections requiring the use of meropenem; 3.Patients requiring empirical or targeted therapy; 4. Patients requiring continuous use of meropenem for more than 2 days, reaching at least one steady-state blood drug concentration; 5. Patients with infections caused by gram-negative bacilli.

Exclusion criteria

Exclusion criteria: 1.Pregnant women, breastfeeding women; 2.Allergic to carbapenems; 3.Simultaneous use of sodium valproate; 4.Gram-positive bacteria, viruses, fungal infections.

Design outcomes

Primary

MeasureTime frame
Blood drug concentration;Embolic events and incidence;ADR/ADE and incidence;—

Secondary

MeasureTime frame
Blood trough concentration;Blood creatinine;—

Countries

China

Contacts

Public ContactYi-yi Qian

Fuwai Yunnan Cardiovascular Hospital

1270117602@qq.com+86 137 0886 1691

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026